Hints and tips:
Related Special Reports
...UBSO: 6; L: 7; I: 7; Total: 20The legal team at the bank advised on the sale of UBS and Mitsubishi’s joint venture, Mitsubishi Corp-UBS Realty, to global investment fund KKR for $2bn....
...Medicago is majority owned by Mitsubishi Tanabe Pharma....
...Toshifumi Tada, head of vaccine business development at Mitsubishi Tanabe Pharma, said its subsidiary Medicago would apply for Canadian approval for its vaccine candidate that is made from a plant from the...
...Medicago, a unit of Mitsubishi Tanabe Pharma that is backed by Philip Morris International, is planning to launch the world’s first plant-based Covid-19 vaccine that is potentially cheaper and easier to...
...Takeda Pharmaceutical has no plans to seek approval in Japan for its dengue fever vaccine, nor does Mitsubishi Tanabe Pharma for an inoculation derived from a tobacco leaf plant....
...Of others joined in the chase, including Mitsubishi Tanabe Pharma, I’rom Group and Takeda Pharmaceutical, the last offers the best chances....
...Tanabe Pharma and Ono Pharmaceutical, both founded three centuries ago....
...In many cases Chinese corporations that were big buyers just a few years ago have been forced to become big sellers. Wu Xiaohui, the chairman of Anbang Insurance, is emblematic of the trend....
...Renesas was originally formed in 2010 through a Japanese government-orchestrated merger of the chip units at Hitachi, Mitsubishi Electric and NEC....
...Shares in Mitsubishi Tanabe Pharma closed 1.2 per cent lower in Tokyo on Monday, a little more than double the decline for the broader Japanese stock market....
...(NYT) A pharma M&A boom could boost innovation: With a wave of pharma mergers potentially on the horizon, companies may be set to unleash a new age of innovation....
...Japan’s Daiichi Sankyo, Mitsubishi Tanabe Pharma and Fujifilm have also said they will enter the fray....
...Mitsubishi Rayon, which bought fellow-acrylic maker Lucite to build a commanding 36 per cent market share, is one example....
...Sumitomo was down 3.0 per cent to Y1,391, Mitsubishi fell by 2.6 per cent to Y3,420 and Marubeni lost 2.2 per cent to Y887....
...Tanabe was down 0.1 per cent to Y1,671, with Mitsubishi Pharma up only 0.7 per cent to Y813. These positive factors outweighed two corporate scandals....
...Other investors include MVM, a biotech investment fund, and MC Life Science Ventures, a subsidiary of Mitsubishi Corporation....
International Edition